ST. LOUIS, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced a major expansion of its Venture Banking team, welcoming a new group of senior bankers, formerly from Silicon Valley Bank, who bring deep expertise across the life sciences and healthcare ecosystem. This strategic move reinforces Stifel’s commitment to supporting innovation-driven companies and investors in sectors such as biotech, diagnostics and tools, medical devices, and healthtech. The new hires are led by M ...

Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launchesCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical ...

COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, advancing the Crown Medical Collections initiative to the key next step. This bankrupt ...

成本削减措施 - 公司计划削减运营成本并裁员约25% [1] - 相关措施与现有运营计划预计将现金跑道延长至2026年第二季度后段 [1]

BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule therapies, today announced that Dr. Rinaldo Montalvão, Director of Artificial Intelligence at Gain Therapeutics, will deliver a talk at the WORLD BI sponsored Drug Discovery Innovation Programme (DDIP) 2025, being held September 25th -26th in Barcelona, Spain. Deta ...

公司活动安排 - 公司将于2025年10月20日东部时间上午8点举办虚拟KOL会议 讨论免疫疗法耐药实体瘤未满足需求及当前治疗格局[1] - 会议将公布第二阶段研究计划及完整1/2期剂量扩展队列数据 包括10月17日ESMO口头报告内容[2] - 正式演讲后将进行现场问答环节[2] 核心产品进展 - 主要候选产品solnerstotug（原SNS-101）为条件活性单克隆抗体 靶向PD-(L)1耐药肿瘤中的VISTA免疫检查点[2] - 该药物通过TMAb™平台开发 旨在选择性阻断肿瘤微环境中低pH条件下的VISTA信号通路[4] - VISTA通过结合PSGL-1受体抑制T细胞功能[4] 专家背景信息 - KOL会议特邀专家Kyriakos Papadopoulos博士为START临床研究联合主任 专精于药物开发及上消化道与肺部恶性肿瘤[3] - 其获得美国国立卫生研究院职业发展奖及癌症研究所Anna-Maria Kellen临床研究者奖[3] - 拥有哥伦比亚大学医师与外科医师学院医学肿瘤学与血液学 fellowship资格[3] 公司技术平台 - 公司专注于肿瘤微环境激活生物制剂（TMAb™）平台开发[4] - 该平台设计条件活性疗法 选择性解除肿瘤微环境的免疫抑制信号或激活免疫刺激信号[4] - 技术旨在特异性释放T细胞对抗肿瘤的能力[4]

VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the "Offering") of 12,727,273 common shares of the Company (the “Common Shares") at a price to the pu ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?It has been a good day for companies involved in peptide drug design and development. News broke this morning that Metsera and its portfolio of glucagon like peptide 1 receptor agonist ("GLP-1 RA") drugs is set to ...

评级与目标价调整 - Guggenheim维持买入评级并将目标价从44美元上调至84美元 反映机构对公司前景的强烈看好[1][5] - 评级调整时公司股价为10美元 目标价上调幅度达91% 显示巨大的潜在上涨空间[1] 药物研发进展 - 核心产品Canvuparatide在二期临床试验中表现优异 12周应答率达63% 6个月应答率提升至79%[2][5] - 治疗期间未出现严重不良事件 安全性数据支持药物进一步开发[2] - 公司计划2026年启动三期临床试验 为药物商业化奠定基础[4] 股价表现与市场数据 - 股价当前报20.51美元 单日涨幅达105.05% 创下显著单日涨幅记录[3][5] - 股价日内交易区间为20-26.45美元 52周波动范围为4.81-27.50美元 显示较高波动性[3] - 公司市值约6.888亿美元 当日成交量达1950万股 市场关注度显著提升[3][4] 投资主题 - 二期临床试验成功成为股价催化因素 投资者对每周一次给药方案的商业化前景持乐观态度[2][3] - 生物技术行业对创新治疗方案的持续关注 为公司价值重估提供行业背景支撑[2][4]

AIM ImmunoTech Inc. (AMEX:AIM) demonstrates remarkable capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly surpassing its peers in the biotechnology sector.The company's ROIC far exceeds its Weighted Average Cost of Capital (WACC), with a ratio of 76.10, indicating efficient use of capital to generate profits.In contrast, peers like Aytu BioPharma, Inc. (AYTU), iBio, Inc. (IBIO), and others show negative ROIC to WACC ratios, highlighting inefficiencies in capital utilizatio ...